None listed
Conditions
Interventions
Others(Auricular acupressure) : Informed consent will be obtained from all participants who are willing to participate in this study. After that, the participants will be divided into two groups accor
three common points
TF4 (Shenmen), CO12 (liver), CO13 (spleen) , and one of them
AH2 (toe), and SF1 (finger) depending on body symptom. The medication-sham acupressure (control group1) and non-mediation-sham acupressure (control group2) will receive sham-auricular acupressure ther
LO1 (tooth), LO2 (tongue), Lo3 (jaw), Lo6 (internal ear). These points were selected based on literature review and consultation from the professionals of acupressure. All participants will visit to r
1) to pressure the attached seeds with appropria
Sponsors
Chungnam National University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: female, at least 20 and under 65years old patients diagnosed with primary breast cancer patients with a diagnosis of Taxane-induced peripheral neuropathy presenting within the last week of an average pain score of at least 5 on a numeric rating scale patients with an ECOG (Eastern Cooperative Oncology Group) performance status of 2 or less patients who are willing and able to comply with the requirements of the study patients who are willing and able to provide written informed consent
Exclusion criteria
Exclusion criteria: Patients with symptoms of peripheral neuropathy that are severe and need to be immediately treated with surgical procedures or acute management Patients with skin inflammation at the attachment site Wearing a hearing aid and piercing Elapsed 12-months after the end of chemotherapy Participants with a history of previous experience of an auricular therapy before enrollment Patients with dementia or cognitive impairment that may affect this study Patients who do not have the ability to read, understand, or respond to questionnaires Receiving Chemotherapy and radiotherapy during the period of the study Patients with a history of receiving other intervention programs during the study Patients with other reasons not to comply with this study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numeric Rating Scale;Chemotherapy Induced Peripheral Neuropathy-20;Total Neuropathy Score | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional Assessment Cancer Therapy-General;Breast Cancer Prevention Trial Symptom Checklist;Patient Health Questionnaire-9;Sources of Social Support Scale;Cancer Coping Questionnaire | — |
Countries
Korea, Republic of
Contacts
Public ContactKim Jung
Chungnam National University
Outcome results
None listed